Trial Profile
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs PCAR 019 (Primary)
- Indications B-cell prolymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoid leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors PersonGen Biomedicine
- 23 Oct 2016 Status changed from not yet recruiting to recruiting.
- 13 Jul 2016 New trial record